Neumora Therapeutics Announces Initiation of Phase 1 Clinical Study of M4 Positive Allosteric Modulator NMRA-861
Provided By GlobeNewswire
Last update: Jul 9, 2025
NMRA-861 has potential best-in-class pharmacology, which may enable a more favorable therapeutic profile
No convulsions observed in pre-clinical studies conducted in multiple species, including rabbits
Read more at globenewswire.com
